NCT07206056 2026-04-16
TulmiSTAR-01
Novartis
Phase 1/2 Recruiting
Clinical Trials
4 trialsNCT07005102 2026-04-15
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
AbbVie
Phase 2/3 Recruiting
NCT03486873 2026-04-13
MK-3475-587
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06585410 2026-04-08
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
Regeneron Pharmaceuticals
Phase 3 Recruiting